MiRxes, a Singapore-based startup focusing on microRNA research and diagnostics, officially launched earlier this month with a proprietary qPCR platform for identifying microRNA and other small RNA biomarkers.

The platform, called mSMRT-qPCR, enables efficient and accurate identification of circulating miRNA biomarkers using existing qPCR workflows, according to the company, which is promoting its use in applications such as early disease detection and patient stratification, prognosis, and treatment response monitoring.